Physician profile
Reed Parker
NPI 1992100390
$5,387.39
in general payments reported to CMS, 2019-2025
27 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $598 · 2021: $626 · 2022: $564 · 2023: $598 · 2024: $957 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.57 |
| Education | $117.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.05 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $677.62 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $479.20 | 2019-2025 | Rocklatan, Clareon, Argos |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $450.55 | 2019-2021 | |
| Allergan, INC. | $355.33 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $269.08 | 2021-2025 | Acthar |
| Glaukos Corporation | $227.42 | 2019-2022 | |
| Dompe US, INC. | $221.08 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $208.71 | 2019-2023 | |
| Rxsight INC | $199.26 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $178.38 | 2019-2025 | Tecnis Iol |
| Thea Pharma INC. | $177.05 | 2024-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $139.76 | 2019 | |
| Shire North American Group INC | $138.25 | 2019 | |
| Bausch & Lomb Americas INC. | $136.70 | 2022-2024 | Miebo, Xiidra, Vyzulta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $128.26 | 2021-2023 | Quatera 700 |
| Biotissue Holdings INC. | $106.07 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $81.81 | 2019-2021 | |
| Ocular Therapeutix, INC. | $72.18 | 2024-2025 | Dextenza |
| Coopervision INC. | $71.86 | 2020 | |
| Horizon Therapeutics Plc | $68.39 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $63.85 | 2022 | |
| Beaver-Visitec International, INC. | $29.37 | 2021-2023 | |
| Mallinckrodt Enterprises LLC | $25.67 | 2019 | |
| New World Medical,INC. | $17.19 | 2022 | |
| Staar Surgical Company | $14.95 | 2019 | |
| Sight Sciences, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.